25E-NBOH
25E-NBOH
Chemical compound
25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent,[2] but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper,[3][4][5] as well as in Slovenia.[6] It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors.[7]